Biopharma firm Kymab has appointed Anne Hyland as chief financial officer, effective from March 1.
Hyland has more than 25 years of financial experience with both public and private firms, most recently serving as chief financial offer (CFO) at BBI Diagnostics and Vectura Group. She additionally serves as non-executive director and chair of the audit committee of Elementis.
Commenting on her appointment, Hyland said: “I am delighted to join Kymab at this exciting time. The significant level of investment the company and management team has attracted is impressive.
“Kymab is a company with tremendous capabilities and talented people and I look forward to helping build further growth and value.”
Prior to her 11-year stint at Vectura, Hyland held roles at Medeva as UK finance director and at KPMG, where she was audit manager.
Dr David Chiswell, chairman and interim CEO of Kymab, said: “I am very pleased to welcome Anne to Kymab’s senior management team. Anne is an experienced CFO with a successful track record of creating value and growth for both public and private companies. Anne’s strong skill set will be invaluable as we build Kymab into a substantial global biopharmaceutical company.”
Kymab is a biopharma firm with a focus on the discovery and development of biologics using its proprietary Kymouse antibody platform.